Cytokinetics (CYTK) Corporate presentation summary

Mission and vision

• Aims to improve healthspan for people with cardiovascular and neuromuscular diseases of impaired muscle function.

• Vision 2030 targets leadership in muscle-focused biopharma, global access, and reaching over 100,000 patients.

• Focus on innovation, patient-centric culture, and equitable access.

Product portfolio and pipeline

• MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the US, EU, and China.

• Pipeline includes aficamten for pediatric oHCM and non-obstructive HCM (nHCM), omecamtiv mecarbil for HFrEF, and ulacamten for HFpEF.

• Multiple late-stage trials ongoing, including MAPLE-HCM, ACACIA-HCM, and COMET-HF.

Clinical evidence and trial results

• SEQUOIA-HCM Phase 3: MYQORZO significantly improved exercise capacity, symptoms, and cardiac structure in oHCM.

• MAPLE-HCM: Aficamten superior to metoprolol in improving pVO2, symptoms, and biomarkers.

• ACACIA-HCM: Statistically significant improvements in KCCQ-CSS and pVO2 for nHCM; no new safety signals.

• Integrated safety analysis shows low incidence of serious adverse events and manageable safety profile for aficamten.